Fifteen early stage chronic lymphocytic leukemia patients were supplemented with escalating n-3 LC-PUFA doses from 2.4 g to 7.2 g/day over 12 months with the highest n-3 LC-PUFA intake level associated with a decrease in Nf-KB activity in subjects with higher Nf-KB activity levels at baseline. The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.